Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estimated pneumococcal vaccination coverage among elderly and adults with chronic medical conditions in Japan
jRCT1030220606Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2023
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of 23-valent pneumococcal polysaccharide vaccine and Prevnar 13 in pneumococcal disease and pneumonia, sponsored by Merck & Co. Primary endpoint: Pneumococcal vaccination rates of PPSV23 and PCV13. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
23-valent pneumococcal polysaccharide vaccinePrevnar 13
03
Conditions
pneumococcal diseasepneumonia
Beyond the preview
Go deeper on jRCT1030220606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030220606.